The results of this study demonstrated that the combination of GSK-J1 and MOF may have synergistic effects in the treatment of carboplatin-resistant ovarian cancer because MOF increased the levels of reactive oxygen species while GSK-J1 reduced HER2 levels in cancer cells. Here, ERBB2 is linked to ovarian carcinoma.